ProQR Therapeutics (PRQR) Stock Price Down 8.3%

Share on StockTwits

ProQR Therapeutics NV (NASDAQ:PRQR)’s share price was down 8.3% during mid-day trading on Thursday . The stock traded as low as $15.05 and last traded at $16.10. Approximately 2,323,302 shares changed hands during trading, an increase of 1,633% from the average daily volume of 134,051 shares. The stock had previously closed at $17.55.

Several equities analysts have recently issued reports on PRQR shares. ValuEngine raised shares of ProQR Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 17th. Zacks Investment Research downgraded shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 6th. HC Wainwright reaffirmed a “buy” rating on shares of ProQR Therapeutics in a research note on Monday, July 2nd. Finally, Chardan Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of ProQR Therapeutics in a research note on Monday, August 13th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. ProQR Therapeutics presently has a consensus rating of “Buy” and an average target price of $13.80.

The company has a market capitalization of $243.73 million, a price-to-earnings ratio of -8.30 and a beta of 0.63. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.02 and a current ratio of 4.02.

ProQR Therapeutics (NASDAQ:PRQR) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.15. equities analysts anticipate that ProQR Therapeutics NV will post -1.35 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in PRQR. Millennium Management LLC bought a new position in ProQR Therapeutics during the second quarter worth $1,426,000. Sphera Funds Management LTD. raised its stake in ProQR Therapeutics by 24.2% during the first quarter. Sphera Funds Management LTD. now owns 658,500 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 128,500 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in ProQR Therapeutics during the second quarter worth $604,000. Ardsley Advisory Partners bought a new position in ProQR Therapeutics during the second quarter worth $365,000. Finally, Jennison Associates LLC raised its stake in ProQR Therapeutics by 1.0% during the second quarter. Jennison Associates LLC now owns 2,981,205 shares of the biopharmaceutical company’s stock worth $21,763,000 after buying an additional 30,831 shares during the last quarter. 34.75% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics (NASDAQ:PRQR)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Recommended Story: Asset Allocation, Balancing Your Investments

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply